Paper40677757
From mechanism to application: programmed cell death pathways in nanomedicine-driven cancer therapies.
Zhang Z and 6 others. Bioact Mater, 2025. Cited by 9 papers, by iCite.
Cite this record
ConductScience Library. From mechanism to application: programmed cell death pathways in nanomedicine-driven cancer therapies. Papers, record 40677757. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40677757
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- From mechanism to application: programmed cell death pathways in nanomedicine-driven cancer therapies.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References317
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32049413 | The Glutathione/Metallothionein System Challenges the Design of Efficient O2 -Activating Copper Complexes. | Angew Chem Int Ed Engl | 2020 | https://conductscience.org/library/papers/32049413 | PubMed |
| 2 | 37344759 | Current status and advances in esophageal drug delivery technology: influence of physiological, pathophysiological and pharmaceutical factors. | Drug Deliv | 2023 | https://conductscience.org/library/papers/37344759 | PubMed |
| 3 | 33408792 | Reducing PD-L1 expression with a self-assembled nanodrug: an alternative to PD-L1 antibody for enhanced chemo-immunotherapy. | Theranostics | 2021 | https://conductscience.org/library/papers/33408792 | PubMed |
| 4 | 38708719 | Human Serum Albumin Mediated Controllable Synthesis of Defect-Rich Copper Hydroxide Nanowire for Cuproptosis-Based Anti-Tumor Therapy. | Adv Healthc Mater | 2024 | https://conductscience.org/library/papers/38708719 | PubMed |
| 5 | 38217522 | Cellular metabolism: A key player in cancer ferroptosis. | Cancer Commun (Lond) | 2024 | https://conductscience.org/library/papers/38217522 | PubMed |
| 6 | 35419582 | Nanoparticle based medicines: approaches for evading and manipulating the mononuclear phagocyte system and potential for clinical translation. | Biomater Sci | 2022 | https://conductscience.org/library/papers/35419582 | PubMed |
| 7 | 37984863 | Cell Death Pathway Regulation by Functional Nanomedicines for Robust Antitumor Immunity. | Adv Sci (Weinh) | 2024 | https://conductscience.org/library/papers/37984863 | PubMed |
| 8 | 31165801 | Recent advances in nanomaterial-based synergistic combination cancer immunotherapy. | Chem Soc Rev | 2019 | https://conductscience.org/library/papers/31165801 | PubMed |
| 9 | 37442270 | Ferroptosis, a new pathogenetic mechanism in cardiometabolic diseases and cancer: Is there a role for statin therapy? | Metabolism | 2023 | https://conductscience.org/library/papers/37442270 | PubMed |
| 10 | 11303500 | Pro-inflammatory programmed cell death. | Trends Microbiol | 2001 | https://conductscience.org/library/papers/11303500 | PubMed |
| 11 | 38799628 | Inhalable metal-organic framework-mediated cuproptosis combined with PD-L1 checkpoint blockade for lung metastasis synergistic immunotherapy. | Acta Pharm Sin B | 2024 | https://conductscience.org/library/papers/38799628 | PubMed |
| 12 | 29348297 | Changes in macrophage transcriptome associate with systemic sclerosis and mediate GSDMA contribution to disease risk. | Ann Rheum Dis | 2018 | https://conductscience.org/library/papers/29348297 | PubMed |
| 13 | 37147285 | KK-LC-1 as a therapeutic target to eliminate ALDH+ stem cells in triple negative breast cancer. | Nat Commun | 2023 | https://conductscience.org/library/papers/37147285 | PubMed |
| 14 | 37820717 | Self-Destructive Copper Carriers Induce Pyroptosis and Cuproptosis for Efficient Tumor Immunotherapy Against Dormant and Recurrent Tumors. | Adv Mater | 2024 | https://conductscience.org/library/papers/37820717 | PubMed |
| 15 | 38364781 | GSDMB is increased in IBD and regulates epithelial restitution/repair independent of pyroptosis. | Cell | 2024 | https://conductscience.org/library/papers/38364781 | PubMed |
| 16 | 39285820 | Multifunctional Copper-Phenolic Nanopills Achieve Comprehensive Polyamines Depletion to Provoke Enhanced Pyroptosis and Cuproptosis for Cancer Immunotherapy. | Adv Mater | 2024 | https://conductscience.org/library/papers/39285820 | PubMed |
| 17 | 39567558 | Regulating copper homeostasis of tumor cells to promote cuproptosis for enhancing breast cancer immunotherapy. | Nat Commun | 2024 | https://conductscience.org/library/papers/39567558 | PubMed |
| 18 | 19626597 | Copper in diseases and treatments, and copper-based anticancer strategies. | Med Res Rev | 2010 | https://conductscience.org/library/papers/19626597 | PubMed |
| 19 | 35606443 | A pyroptosis nanotuner for cancer therapy. | Nat Nanotechnol | 2022 | https://conductscience.org/library/papers/35606443 | PubMed |
| 20 | 37880907 | Photoinduced Cuproptosis with Tumor-Specific for Metastasis-Inhibited Cancer Therapy. | Small | 2024 | https://conductscience.org/library/papers/37880907 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42934669 | Trace elements and tumors: homeostatic networks, molecular mechanisms and new horizons for precision intervention. | Mol Cancer | 2026 | https://conductscience.org/library/papers/42934669 | PubMed |
| 42422020 | PROTAC-mediated regulation of programmed cell death: From molecular mechanisms to therapeutic breakthroughs. | Innovation (Camb) | 2026 | https://conductscience.org/library/papers/42422020 | PubMed |
| 41820292 | Harnessing pyroptosis in breast cancer therapy: immunological mechanisms and emerging biomaterial strategies. | Cell Death Discov | 2026 | https://conductscience.org/library/papers/41820292 | PubMed |
| 41597186 | Non-Apoptotic Programmed Cell Death: From Ultrastructural Characterization to Emerging Therapeutic Opportunities. | Cells | 2026 | https://conductscience.org/library/papers/41597186 | PubMed |
| 41201667 | Targeting ferroptosis and cuproptosis in gastrointestinal cancers: molecular mechanisms, metabolic vulnerabilities, and therapeutic interventions. | Mol Biomed | 2025 | https://conductscience.org/library/papers/41201667 | PubMed |
| 41097635 | The FSIP Family: Roles in Health and Cancer. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41097635 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40677757
GET https://conductscience.org/api/papers/v1/40677757/references?page=2